University Hospitals Announces its Participation in Novel Clinical Trial Testing Multiple Therapeutics to Treat COVID-19

ACTIV-2 will evaluate the safety and efficacy of investigational treatments for adults who have COVID-19, but do not require hospitalization. ACTIV-2 is a randomized, blinded, controlled study that tests a variety of new agents against placebo. This approach allows promising investigational agents to be added and removed over the course of the study.

Woman recovering from COVID-19 shares experience as monoclonal antibody clinical trial participant

When Christina Loville tested positive for the coronavirus, she was terrified. She decided to channel her fear into researching COVID-19 treatments, where she discovered a local clinical trial led by experts at The University of Texas Health Science Center at Houston (UTHealth).

UTHealth joins NIH trial to test antibodies and other experimental outpatient treatments for mild COVID-19 pneumonia

A study on the effectiveness of multiple treatments, including laboratory-made antibodies, at preventing mild COVID-19 from advancing to severe illness in the outpatient setting is underway by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.